Lytix Biopharma – Minutes of Ordinary General Meeting

Oslo, Norway, May 14, 2024 – The Ordinary General Meeting of Lytix Biopharma AS ("Lytix" or the "Company") was held on May 14, 2024. All proposed resolutions on the agenda were approved.

Minutes of the meeting are attached hereto.

The minutes and all documents relevant for the annual general meeting are available on the Company's website.

For more information, please contact:

Gjest Breistein, CFO

+47 952 60 512

gjest.breistein@lytixbiopharma.com

About Lytix

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.